SIMCERE PHARMA (02096) plans to acquire all equity of Shanghai Xiansheng Diagnostic Technology for 30.76 million yuan, aiming to create an open innovation exchange center.

SIMCERE PHARMA (02096) announced that on March 25, 2026, the buyer SIMCERE PHARMA Limited (an indirect wholly-owned subsidiary of the Company) entered into a share transfer agreement with the seller Jiangsu Xiansheng Diagnostic Technology Co., Ltd. The buyer agreed to acquire and the seller agreed to sell all the equity interests in the target company Shanghai Xiansheng Diagnostic Technology Co., Ltd. for a cash consideration of RMB 30,763,200. After the completion of the acquisition, the target company will become an indirect wholly-owned subsidiary of the Company, and the financial performance of the target company will be consolidated into the Group's financial statements. The target company owns the land use right of a piece of land located in Huacao Town, Minhang District, Shanghai, China, with a total land area of 5950.60 square meters (the target land). There is an ongoing construction project on the target land which has been temporarily suspended and only preliminary work is being carried out. The acquisition aims to establish an open innovation exchange center, which is an important strategic facility for implementing the innovation-driven development strategy. As a strategic facility, the center will establish an industrial incubation transformation platform to expand and attract a group of high-potential innovative entities for cooperation. It will also build supporting living facilities to meet the needs of talent introduction, project cooperation, academic exchanges, etc. The center aims to create an innovative platform that gathers the Group's innovative resources, strengthens its external interaction capabilities, encourages international industry partners to establish offices, promotes the deep integration of global R&D resources with China's life science innovation ecology, introduces a batch of innovative projects for incubation, carries out forward-looking layouts, seizes disruptive innovation opportunities. It is expected that the center will significantly enhance the Group's ability for external cooperation, thereby strengthening its innovation upgrade and strategic response capabilities. Due to the need for continuous business expansion and enhancement of innovation capabilities, the Group will continue to increase its talent density, attract and reserve more outstanding talent, and establish a sound mechanism for the selection, appointment, training, and retention of high-level talents. Living facilities are important support for attracting high-end talents. Currently, the existing living support resources of the Group are increasingly constrained in meeting the future talent reserve needs. To overcome the existing limitations, the construction of centralized living facilities has become a strategic necessity. The target land is considered an ideal location for the development of the center due to its superior geographical location and compliance with the planned use. Its convenient transportation conditions and the advantages of being near the Group's personnel and external partners will help optimize travel arrangements and establish a stable and sustainable communication hub. As the target land has already undergone preliminary construction, the acquisition can significantly shorten the completion schedule of the center compared to starting a new construction cycle at a new site, avoiding duplicate investments and reducing project uncertainties. The acquisition is highly in line with the Group's operational planning and strategic development goals, supporting the Group's long-term growth and market competitiveness in an increasingly dynamic business environment.